Literature DB >> 20629009

Synergistic action of oncolytic herpes simplex virus and radiotherapy in pancreatic cancer cell lines.

M-H Dai1, D Zamarin, S P Gao, T-C Chou, L Gonzalez, S-F Lin, Y Fong.   

Abstract

BACKGROUND: Despite much research in chemotherapy and radiotherapy, pancreatic adenocarcinoma remains a fatal disease, highly resistant to all treatment modalities. Recent developments in the field of herpes simplex virus (HSV) engineering have allowed the generation of a number of promising virus vectors for treatment of many cancers, including pancreatic tumours. This study examined the use of one such virus, NV1023, in combination with radiation therapy in pancreatic cancer cell lines.
METHODS: HSV therapy in combination with radiotherapy was investigated in pancreatic cancer cell lines Hs766T, Panc-1 and MIA PaCa-2. Multiple therapy effect analysis was performed by computerized simulation. Mechanisms underlying synergy, such as virus replication and apoptosis, were investigated.
RESULTS: The combination of NV1023 and radiation yielded a synergistic oncolytic effect in all tested pancreatic cancer cell lines, with the greatest effect achieved in MIA PaCa-2. This effect was not mediated by an increase in rapid viral replication, but by a substantial increase in apoptosis.
CONCLUSION: The synergistic oncolytic actions of HSV and radiotherapy observed in pancreatic cancer cell lines encourage further testing of this multimodality treatment. Copyright 2010 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20629009     DOI: 10.1002/bjs.7124

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  13 in total

Review 1.  Pancreatic cancer from bench to bedside: molecular pathways and treatment options.

Authors:  Christoforos Kosmidis; Konstantinos Sapalidis; Efstathios Kotidis; Nikolaos Mixalopoulos; Paul Zarogoulidis; Drosos Tsavlis; Sofia Baka; Yan-Gao Man; John Kanellos
Journal:  Ann Transl Med       Date:  2016-05

Review 2.  Thunder and lightning: immunotherapy and oncolytic viruses collide.

Authors:  Alan Melcher; Kelley Parato; Cliona M Rooney; John C Bell
Journal:  Mol Ther       Date:  2011-04-19       Impact factor: 11.454

Review 3.  Viro-immune therapy: A new strategy for treatment of pancreatic cancer.

Authors:  Andrea Marie Ibrahim; Yao-He Wang
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

4.  The effects of radiation on antitumor efficacy of an oncolytic adenovirus vector in the Syrian hamster model.

Authors:  B A Young; J F Spencer; B Ying; K Toth; W S M Wold
Journal:  Cancer Gene Ther       Date:  2013-08-09       Impact factor: 5.987

Review 5.  Vaccinia virus, a promising new therapeutic agent for pancreatic cancer.

Authors:  Chadwan Al Yaghchi; Zhongxian Zhang; Ghassan Alusi; Nicholas R Lemoine; Yaohe Wang
Journal:  Immunotherapy       Date:  2015-11-23       Impact factor: 4.196

6.  Natural oncolytic activity of live-attenuated measles virus against human lung and colorectal adenocarcinomas.

Authors:  Nicolas Boisgerault; Jean-Baptiste Guillerme; Daniel Pouliquen; Mariana Mesel-Lemoine; Carole Achard; Chantal Combredet; Jean-François Fonteneau; Frédéric Tangy; Marc Grégoire
Journal:  Biomed Res Int       Date:  2013-03-17       Impact factor: 3.411

7.  Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of neuroblastoma.

Authors:  Lauren A Gillory; Michael L Megison; Jerry E Stewart; Elizabeth Mroczek-Musulman; Hugh C Nabers; Alicia M Waters; Virginia Kelly; Jennifer M Coleman; James M Markert; G Yancey Gillespie; Gregory K Friedman; Elizabeth A Beierle
Journal:  PLoS One       Date:  2013-10-10       Impact factor: 3.240

Review 8.  Oncolytic viral therapy for pancreatic cancer: current research and future directions.

Authors:  Justin W Ady; Jacqueline Heffner; Elizabeth Klein; Yuman Fong
Journal:  Oncolytic Virother       Date:  2014-02-17

Review 9.  Oncolytic virotherapy using herpes simplex virus: how far have we come?

Authors:  Nicolas As Sokolowski; Helen Rizos; Russell J Diefenbach
Journal:  Oncolytic Virother       Date:  2015-11-25

10.  Effect of Repeat Dosing of Engineered Oncolytic Herpes Simplex Virus on Preclinical Models of Rhabdomyosarcoma.

Authors:  Alicia M Waters; Laura L Stafman; Evan F Garner; Smitha Mruthyunjayappa; Jerry E Stewart; Gregory K Friedman; Jennifer M Coleman; James M Markert; G Yancey Gillespie; Elizabeth A Beierle
Journal:  Transl Oncol       Date:  2016-10       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.